Tocilizumab in adult-onset Still's disease: the Israeli experience.

Overview of attention for article published in Journal of Rheumatology, January 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

policy: 1 policy source

twitter: 8 X users

Citations

dimensions_citation: 43 Dimensions

Readers on

mendeley: 51 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 14,744 followers.

5-6-2020: This 500-participant Israeli COVID-19 clinical trial might not go well for Actemra (tocilizumab). The 2-to-1 ratio makes it more likely that the healthier patients will end up in the placebo group https://t.co/VYMleSWWSw https://t.co/6ZdXQgoW4a

06 Nov 2020

Reply Repost Favourite

Tocilizumab for adult onset still's disease http://t.co/JUvxk7xNNI #rheum

08 Feb 2014

Reply Repost Favourite

Tocilizumab for adult onset still's disease http://t.co/JUvxk7xNNI #rheum

03 Feb 2014

Reply Repost Favourite

Tocilizumab for adult onset still's disease http://t.co/JUvxk7xNNI #rheum

03 Feb 2014

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.